What Scorpion alleged
Scorpion Capital Partners LP labeled obefazimod a toxin and, in a post on X, argued its fat solubility resembles that seen in prohibited pesticides and some industrial compounds, a characteristic it says Abivax omitted to disclose. The short seller also said its own lab tests suggest the drug could be a photocarcinogen, meaning a substance that may trigger cancer following light exposure. It further asserted that much of Abivax's research leans on studies published in China and cited a scientific paper that was later retracted.
How Abivax responded
Abivax countered late Friday, saying the analysis "contains numerous factually inaccurate and misleading statements, assumptions, and conclusions, including those based on studies commissioned and funded by Scorpion Capital itself." The company said it stands by its clinical results and still plans to submit an application to the US Food and Drug Administration before yearend.
The backdrop and what moved the stock
Cancer risk has been a recurring worry around obefazimod in inflammatory bowel disease. Abivax has previously reported cancer cases in an ulcerative colitis study, noting the tumors occurred in patients already at risk and, in some instances, in those with a prior history of skin cancer. The same drug is also in testing for Crohn's disease. Shares dropped 17% in Paris on Friday, extending their year-to-date slide to 48%.
When uncertainty surrounds company news and analysis, sign up for the free Market Briefs newsletter that arrives each morning
Why it matters for investors
Abivax has long been a takeover talking point, which has amplified its price swings. Before the obefazimod trial readout, the stock climbed on hopes that positive data would unlock a large market. The latest short call hit an already volatile name, reminding portfolios that binary drug headlines can overwhelm fundamentals in the short run.
When headlines about drugs and disclosures appear, sign up for the free daily Market Briefs to get clear context in minutes
